Embryo implantation
AssigneeOstara Biomedical Ltd.
InventorsNadia Gopichandran, Nicolas Michel Orsi, David Andrew Brooke
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of and compositions comprising cytokines for, improving the success rate of embryo implantation and the success rate of pregnancy rates in females, by providing an immunopermissive uterine environment prior to insemination or implantation of embryos. The methods of the present invention are used to make the uterus more receptive or less hostile to, for example, transferred embryos, sperm or other allografted tissue.
Claims17
A composition consisting essentially of a recombinant eotaxin and a recombinant RANTES, wherein the composition releases the recombinant eotaxin and the recombinant RANTES in situ in a vagina within a physiological concentration range as corresponding eotaxin and RANTES found in seminal fluid of a fertile male.
A composition consisting essentially of a recombinant eotaxin, a recombinant RANTES, and one or more recombinant cytokines selected from the group consisting of TNF-α, TGF-β, IL-12, MCP-1, MIP, IL-17, IL-9, GM-CSF and combinations thereof, wherein the composition releases the recombinant eotaxin, the recombinant RANTES, and the one or more recombinant cytokines in situ in a vagina within a physiological concentration range as corresponding eotaxin, RANTES, and cytokines selected from the group consisting of TNF-α, TGF-β, IL-12, MCP-1, MIP, IL-17, IL-9 and GM-CSF found in seminal fluid of a fertile male.
A method of reducing maternal alloreactivity against seminal fluid, sperm, or an embryo, the method comprising:
- (i) exposing a vaginal mucosa to a composition consisting essentially of a recombinant eotaxin and a recombinant RANTES, wherein the composition releases the recombinant eotaxin and the recombinant RANTES in situ in a vagina within a physiological concentration range as corresponding eotaxin and RANTES found in seminal fluid of a fertile male;
- (ii) introducing at least one vaginal delivery vehicle comprising the composition consisting essentially of the recombinant eotaxin and the recombinant RANTES into the vagina of a female, wherein the recombinant eotaxin and the recombinant RANTES are active ingredients;
- (iii) allowing a sufficient period of time to elapse to allow the active ingredients of the vaginal delivery vehicle to be released and to penetrate into the vagina and be absorbed into a uterus;
- and
- (iv) inseminating the female by either mating with a male or by artificial insemination, donor gametes or introducing an embryo into the uterus for implantation.
A method of improving pregnancy rate or outcome in a female prior to insemination or implantation of an embryo, the method comprising:
- (i) exposing a vaginal mucosa to a composition consisting essentially of a recombinant eotaxin and a recombinant RANTES, wherein the composition releases the recombinant eotaxin and the recombinant RANTES in situ in a vagina within a physiological concentration range as corresponding eotaxin and RANTES found in seminal fluid of a fertile male;
- (ii) introducing at least one vaginal delivery vehicle comprising the composition consisting essentially of the recombinant eotaxin and the recombinant RANTES into the vagina of the female, wherein the recombinant eotaxin and the recombinant RANTES are active ingredients;
- (iii) allowing a sufficient period of time to elapse to allow the active ingredients of the vaginal delivery vehicle to be released and to penetrate into the vagina and be absorbed into a uterus;
- and
- (iv) inseminating the female by either mating with a male or by artificial insemination, donor gametes or introducing an embryo into the uterus for implantation.
Dependencies are inferred from the claim text.